OBJECTIVE: To investigate the relationship of the polymorphic enhancer HS1,2 central to the 3' enhancer complex regulatory region (IgH3'EC) of the immunoglobulin heavy chain genes with systemic sclerosis (SSc) disease and compare it with HLA-DR and DQ associations. METHODS: A total of 116 patients with SSc were classified as diffuse (dSSc) or limited (lSSc), and as carriers of antitopoisomerase I (anti-Scl70) or anticentromere (ACA) antibodies. Allele and genotype frequencies were assessed in the population as a whole and in the two major subsets, dSSc and lSSc. The concentration of peripheral blood immunoglobulin levels was also determined and analysed according to the genotypes. RESULTS: The analysis of genotypes for the four alleles of the HS1,2A enhancer showed an increased frequency of allele *2 in the SSc cohort highly significant versus controls (57% vs. 40%, p<0.0001). Considering the autoantibody pattern, we found that the frequency of the 2/2 genotype was increased in ACA+ patients (42%) and anti-Scl70+ patients (31%) compared with the control group (15%). The differences of allelic frequencies among dSSc versus lSSc or ACA+ versus anti-Scl70+ patients were not significant, although highly significant when comparing each subgroup with the control group. HLA-DRB1*11 and DQB1*03 associated with SSc. No association was seen between HS1,2A enhancer polymorphism and HLA alleles. CONCLUSIONS: These data confirm there was an increased risk of having SSc in carriers of allele *2, suggesting an intriguing function of this polymorphism for B-cell regulation.
OBJECTIVE: To investigate the relationship of the polymorphic enhancer HS1,2 central to the 3' enhancer complex regulatory region (IgH3'EC) of the immunoglobulin heavy chain genes with systemic sclerosis (SSc) disease and compare it with HLA-DR and DQ associations. METHODS: A total of 116 patients with SSc were classified as diffuse (dSSc) or limited (lSSc), and as carriers of antitopoisomerase I (anti-Scl70) or anticentromere (ACA) antibodies. Allele and genotype frequencies were assessed in the population as a whole and in the two major subsets, dSSc and lSSc. The concentration of peripheral blood immunoglobulin levels was also determined and analysed according to the genotypes. RESULTS: The analysis of genotypes for the four alleles of the HS1,2A enhancer showed an increased frequency of allele *2 in the SSc cohort highly significant versus controls (57% vs. 40%, p<0.0001). Considering the autoantibody pattern, we found that the frequency of the 2/2 genotype was increased in ACA+ patients (42%) and anti-Scl70+ patients (31%) compared with the control group (15%). The differences of allelic frequencies among dSSc versus lSSc or ACA+ versus anti-Scl70+ patients were not significant, although highly significant when comparing each subgroup with the control group. HLA-DRB1*11 and DQB1*03 associated with SSc. No association was seen between HS1,2A enhancer polymorphism and HLA alleles. CONCLUSIONS: These data confirm there was an increased risk of having SSc in carriers of allele *2, suggesting an intriguing function of this polymorphism for B-cell regulation.
Authors: Robert A Barrington; Ming Zhang; Xuemei Zhong; Helena Jonsson; Nichol Holodick; Anu Cherukuri; Susan K Pierce; Thomas L Rothstein; Michael C Carroll Journal: J Immunol Date: 2005-09-01 Impact factor: 5.422
Authors: J D Reveille; M Fischbach; T McNearney; A W Friedman; M B Aguilar; J Lisse; M J Fritzler; C Ahn; F C Arnett Journal: Semin Arthritis Rheum Date: 2001-04 Impact factor: 5.532
Authors: Pierre Youinou; Christophe Jamin; Jacques-Olivier Pers; Christian Berthou; Alain Saraux; Yves Renaudineau Journal: Ann N Y Acad Sci Date: 2005-06 Impact factor: 5.691
Authors: Natalia Kovalova; Michael D Knierman; Patricia L Brown-Augsburger; Victor J Wroblewski; Lukasz K Chlewicki Journal: Immunogenetics Date: 2019-11-27 Impact factor: 2.846
Authors: Lorenzo Beretta; Blanca Rueda; Maurizio Marchini; Alessandro Santaniello; Carmen P Simeón; Vicente Fonollosa; Monica Caronni; Raquel Rios-Fernandez; Patricia Carreira; Luis Rodriguez-Rodriguez; Antonia Moreno; Miguel A López-Nevot; Ana Escalera; Maria F González-Escribano; Javier Martin; Raffaella Scorza Journal: Rheumatology (Oxford) Date: 2011-11-15 Impact factor: 7.580
Authors: Tharu M Fernando; Sharon D Ochs; Jing Liu; Ruth C Chambers-Turner; Courtney E W Sulentic Journal: J Immunol Date: 2012-02-22 Impact factor: 5.422
Authors: D Frezza; V Giambra; C Mattioli; K Piccoli; R Massoud; A Siracusano; M Di Giannantonio; B K Birshtein; I A Rubino Journal: Int J Immunopathol Pharmacol Date: 2009 Jan-Mar Impact factor: 3.219
Authors: B Tolusso; D Frezza; C Mattioli; A L Fedele; S Bosello; F Faustini; G Peluso; V Giambra; D Pietrapertosa; A Morelli; E Gremese; M De Santis; G F Ferraccioli Journal: Ann Rheum Dis Date: 2008-10-24 Impact factor: 19.103